Bristol-Myers Squibb Co. reported a first-quarter profit beat and revenue miss early Thursday and changed its 2018 profit outlook. Earnings for the latest quarter declined to $1.49 billion, or 91 cents per share, from $1.57 billion, or 94 cents per share in the year-earlier period. Adjusted earnings-per-share were 94 cents, compared with the FactSet consensus of 85 cents. Revenue rose to $5.19 billion from $4.93 billion, compared with the FactSet consensus of $5.25 billion. Opdivo, Eliquis and Orencia sales beat the FactSet consensus, while Sprycel, Yervoy and Empliciti sales came in below consensus. Bristol-Myers also lowered its 2018 EPS outlook from $3.00 to $3.15 to $2.70 to $2.80 and increased its 2018 adjusted EPS outlook from $3.15 to $3.30 to $3.35 to $3.45. Company shares lifted 0.4% premarket. Shares have plummeted 19% over the last three months, compared with an 8% drop in the S&P 500 and a 9.5% drop in the Dow Jones Industrial Average